Full Press Release Details
Cellectar Biosciences Reports Third Quarter
Financial and Corporate Performance
Madison, Wisc. (November
09, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage
biotechnology company (the "company"), today reported financial results and corporate
performance for the third quarter ended September 30, 2017.
Summary of Q3 and Q4 2017 Accomplishments to Date
"We continue to leverage our PDC delivery
platform as we execute on the components of our corporate growth strategy which includes the CLR 131 franchise, our in-house PDC
R&D program and our collaboration model," said Jim Caruso, president and CEO of Cellectar Biosciences. "During
the quarter, we reported very encouraging results from our Phase 1 clinical trial of CLR 131 in multiple myeloma and our preclinical
programs, extended and expanded collaborations with Pierre Fabre and the University of Wisconsin and initiated two additional strategic
collaborations with Avicenna and Onconova to cost effectively accelerate our PDC research and development programming."
Third Quarter 2017 Financial Results
Cash and cash equivalents as of September 30, 2017 were approximately
$5.7 million compared to approximately $11.4 million as of December 31, 2016. Subsequent to the end of the quarter, Cellectar raised
net proceeds of approximately $7.0 million in a registered direct offering of 1,954,388 shares of common stock and 41.0412949
shares of Series B preferred stock, which are immediately convertible into approximately 53,369 shares of common stock for a total
of 2,190,330 shares, together with a private placement of Series D warrants convertible into 3,108,538 shares of common stock.
The proceeds will be used for general corporate purposes, including working capital.
Cellectar reported a net loss of approximately $3.5 million,
or $0.26 per common share (basic and diluted), for the three months ended September 30, 2017 as compared to $2.3 million, or $0.43
per share for the three months ended September 30, 2016. The results included non-cash, stock based compensation charges of approximately
$176,000, in the third quarter of 2017 and approximately $174,000 in the third quarter of 2016. Net losses have resulted primarily
from costs incurred in connection with research and development programs and from general and administrative costs associated with
Research and development expenses were approximately $2.3 million
for the three months ended September 30, 2017 compared to $1.3 million for the three months ended September 30, 2016. The increase
in the company's R&D spending is primarily due to increased preclinical development costs, as well as increased support
for the ongoing Phase 2 clinical trial in hematologic malignancies. Investment in the company's ongoing Phase 1 relapsed/refractory
multiple myeloma trial remained relatively consistent.
General and administrative expenses were approximately $1.2
million for both the three months ended September 30, 2017 and three months ended September 30, 2016.
Conference Call Details
Cellectar will be holding a
conference call at 8:00 AM ET tomorrow, November 10, 2017, to review Q3 2017 financial results, and corporate performance.
The call may be accessed by dialing 888-646-8293 (US domestic) or 973-453-3065 (international) with audience passcode
7286449, or participate via webcast at https://edge.media-server.com/m6/p/gu4wgk2s. The
live and archived webcast can also be accessed via the company's website at http://investor.cellectar.com/events.cfm.
About Cellectar Biosciences, Inc.
Cellectar Biosciences (Nasdaq: CLRB) is developing phospholipid drug conjugates (PDCs) designed
to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's
PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly
selective uptake and retention in a broad range of cancers, even sites of metastases. The company's lead therapeutic PDC, CLR
131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 has been designated as an orphan drug by the US FDA
and is currently being evaluated in a Phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a Phase
2 clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing proprietary PDCs for targeted
delivery of chemotherapeutics and has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic
pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may," "expect," "believe," "anticipate,"
"intend," "could," "estimate," "continue," "plans," or their negatives or cognates.
These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause
actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical
companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business
is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended
December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to
update any such forward-looking statements.